Mortality in a population-based cohort of patients treated with antiparkinsonian drugs.
A number of studies have been focused on the mortality of parkinsonian patients. as compared with the rest of the population.
In these studies, a mortality greater than expected on the basis of mortality of the general population has been shown.
Nevertheless, just a few of these studies have investigated in detail the specific causes of death, probably as a consequence of both small cohort sizes and a short time period of observation.
The aim of this study was to estimate cause-specific mortality in a cohort of patients treated with antiparkinsonian drugs.
The study was performed on a wide population-based cohort of patients identified and followed-up through the computerized health databases of the Italian province of Rome (about 3.800.000 inhabitants).
The follow-up lasted from January 1987 to December 1994.
Standardized Mortality Ratios (SMR) were calculated for each specific cause of death, using the Rome province population as reference.
A cohort of 10,322 subjects. receiving antiparkinsonian drugs, were identified.
There were 4328 deaths on an average follow-up of 5.7 years.
This figure was 17% higher than was expected.
A gradual decrease in SMR was observed in the oldest age groups.
Statistically significant (95%) excesses of death were related to the nervous system (SMR=1037 ; 95% CI 964-1110, mental disorders (SMR=182 ; 95% CI 129-246), and endocrine and metabolic diseases (SMR=117 ; 95% Cl 102-133). (...)
Mots-clés Pascal : Mortalité, Etude cohorte, Antiparkinsonien, Chimiothérapie, Italie, Europe, Epidémiologie, Etiologie, Traitement, Homme
Mots-clés Pascal anglais : Mortality, Cohort study, Antiparkinson agent, Chemotherapy, Italy, Europe, Epidemiology, Etiology, Treatment, Human
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 98-0094874
Code Inist : 002B02B06. Création : 14/05/1998.